Table 2.
Summary of extracted outcome data and pooled analysis
| Study | LM ORR (%) | LM DCR (%) | PFS (moths) | OS (moths) | 1-y OS rate (%) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 95% CI | Median | 95% CI | Median | 95% CI | Median | 95% CI | |||||
| Yang 2019 | 62 (23/37) | 45–78 | 95 (35/37) | 82–99 | 8.6 | 5.4–13.7 | 11.0 | 8.0–18.0 | 48.8 | |||
| Lee 2020 | NA | NA | NA | NA | NA | NA | 17.0 | 15.1–18.9 | 61.8 | |||
| Ahn 2020 | 55 (12/22) | 32–76 | 91 (20/22) | NA | 11.1 | 4.6-NR | 18.8 | 6.3-NR | 63.6 | |||
| Park 2020 | 12.5 (5/40) | NA | 92.5 (37/40) | NA | 8.0 | 7.2-NR | 13.3 | 9.1-NR | 55.0 | |||
| Nanjo 2017 | NA) | NA | NA | NA | NA | NA | NR | NA | NA | |||
| Zheng 2020 | 38.2 (13/34) | NA | NA | NA | 15.6a | 4.0–17.2a | NA | NA | NA | |||
| 7.0b | 4.0–10.0b | |||||||||||
| Saboundji 2018 | NA | NA | NA | NA | 17.3 | 2.7–20.8 | 18.0 | 4.4–23.8 | 65.0 | |||
| Reungwetwattana 2018 | 80 (4/5) | NA | 100 (5/5) | NA | NA | NA | NA | NA | NA | |||
| Akazawa 2019 | 33.3 (2/6) | NA | 83.3 (5/6) | NA | 3.7 | NA | NR | NA | NA | |||
| Ahn 2019 | 25 (10/40) | NA | 90 (36/40) | NA | NA | NA | 13.2 | NA | NA | |||
| Andrew 2020 | NA | NA | NA | NA | 5.8 | 1.7–9.0 | NA | NA | NA | |||
| Meta-analysis | 42 | 24–59 | 90 | 85–94 | NA | NA | NA | NA | 59 (53–65) | |||
CI: confidence interval; DCR: disease control rate; LM: leptomeningeal metastases; NA: not available; ORR: overall response rate; OS: overall survival; PFS: progression free survival
aT790M + patients
bT790M- patients